Announced details
Relapsed or refractory acute myeloid leukemia with an IDH1 gene mutation
In September 2024, KISSEI PHARMACEUTICAL CO., LTD. acquired exclusive development and commercialization rights for olutasidenib in Japan, South Korea and Taiwan from Rigel Pharmaceuticals, Inc. KISSEI PHARMACEUTICAL CO., LTD. is the licensor to Orient EuroPharma Co., Ltd.
Rigel Pharmaceuticals, Inc.: A Nasdaq-listed biotechnology company headquartered in California, USA, focused on discovering, developing and providing treatments for patients with hematologic diseases and cancer. Established in 1996; President and CEO: Raul Rodriguez. Orient EuroPharma Co., Ltd.: Based in Taiwan; Chairman: Peter Tsai.
The impact of this matter on the earnings forecast has been incorporated into the consolidated earnings forecast for the fiscal year ending March 2027.
The company does not address Contract Value / Offering price.
Blood (2015) 126 (3): 319-27
Leukaemia Care. Relapse in Acute Myeloid Leukaemia. Version 3
NCCN Guidelines 2026 V3
| Item | Details |
|---|---|
| Names of Products / Services Covered | Olutasidenib (generic name) |
| Counterparty | Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), Orient EuroPharma Co., Ltd. |
| Counterparty overview | Rigel Pharmaceuticals, Inc.: A Nasdaq-listed biotechnology company headquartered in California, USA, focused on discovering, developing and providing treatments for patients with hematologic diseases and cancer. Established in 1996; President and CEO: Raul Rodriguez. Orient EuroPharma Co., Ltd.: Based in Taiwan; Chairman: Peter Tsai. |
| Relationship with the Company | In September 2024, KISSEI PHARMACEUTICAL CO., LTD. acquired exclusive development and commercialization rights for olutasidenib in Japan, South Korea and Taiwan from Rigel Pharmaceuticals, Inc. KISSEI PHARMACEUTICAL CO., LTD. is the licensor to Orient EuroPharma Co., Ltd. |
| Contract Date | September 2024 (in-license agreement with Rigel Pharmaceuticals, Inc.) / 1 May 2026 (out-license agreement with Orient EuroPharma Co., Ltd.) |
| Applicable area | Relapsed or refractory acute myeloid leukemia with an IDH1 gene mutation |
| Impact on Business Performance | The impact of this matter on the earnings forecast has been incorporated into the consolidated earnings forecast for the fiscal year ending March 2027. |
| Source | Blood (2015) 126 (3): 319-27, Leukaemia Care. Relapse in Acute Myeloid Leukaemia. Version 3, NCCN Guidelines 2026 V3 |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To focus on rare diseases and diseases for which adequate treatments are unavailable, and to provide patients with new treatment options.